BeOne Medicines Ltd ADR (ONC) — Titan Protect Analysis

ONC

BeOne Medicines Ltd ADR

Healthcare · ·

$270.10

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$28.6B

Total market value of the company

Trailing P/E

62.30

Expensive — high growth expected

Forward P/E

28.85

Based on estimated future earnings — lower means cheaper

Rev Growth

+35.5%

Year-over-year revenue change

Profit Margin

8.9%

How much profit the company keeps from each dollar of revenue

ROE

12.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$410.50

+52% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 28 analysts covering this stock

About BeOne Medicines Ltd ADR

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multic

https://beonemedicines.com

Country: Switzerland Employees: 12,000 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.873

Good returns relative to risk taken

Kelly Fraction

0.0704

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.135

Returns exceed worst-case losses — strong risk profile

Annual Return

32.9%

Historical annualised return based on price data

Max Drawdown

-29.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.50

Less volatile than the market — more defensive

52W High

$385.22

30% below the year high

52W Low

$239.25

13% above the year low

Avg Volume

227,100

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$4.42

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.14

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

88.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

16.5%

Profit from core operations before interest and tax

Free Cash Flow

$917M

Positive — the business generates more cash than it spends

Revenue (TTM)

$5.7B

Total revenue over the last 12 months

Net Income

$513M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$501.30

Target Median

$410.50

Target Low

$333.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go